[1] Rouabhia S, Milic N, Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol, 2014, 8:343-349.
[2] 刘江奎,沈毅慧,刘翔川,等.替米沙坦对非酒精性脂肪性肝炎大鼠的保护作用及其机制.中华肝脏病杂志, 2011, 19:614-618.
[3] 沈毅慧,刘江奎,何敬堂,等.替米沙坦对非酒精性脂肪性肝炎大鼠脂联素及PPAR-γ表达的影响. 医药导报, 2011, 30: 15-18.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2010,18:161-166.
[5] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up.J Hepatol, 2012, 56:1145-1151.
[6] 施军平,荀运浩. 非酒精性脂肪性肝病治疗进展. 实用肝脏病杂志, 2013, 6: 493-495.
[7] Varela-Rey M, Embade N, Ariz U, et al. Martinez-Chantar ML.Non-alcoholic steatohepatitis and animal models:understanding the human disease.Int J Biochem Cell Biol,2009, 41:969-976
[8] Yoneda M1, Mawatari H, Fujita K, Iida H, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol, 2007,42:573-582.
[9] Paradies G, ParadiesV, Ruggiero FM, et al. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20:14205-14218.
[10] Zahran WE, Salah El-Dien KA, Kamel PG, et al. Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression. Indian J Clin Biochem, 2013, 28:141-146. |
